Reno Debets

This paper designs TCRs with ICOS to improve T cell therapy, showing durable anti-tumor effects and resistance to exhaustion in mice and humans.

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

CLEAR-IT improves cell phenotyping in tumor microenvironments by using contrastive learning, outperforming existing methods across imaging modalities and requiring fewer labels.